Axitinib
- Generic Name
- Axitinib
- Brand Names
- Inlyta, Axitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N4OS
- CAS Number
- 319460-85-0
- Unique Ingredient Identifier
- C9LVQ0YUXG
Overview
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Background
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indication
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Associated Conditions
- Advanced Renal Cell Carcinoma
- Advanced Thyroid cancer
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.